Skip to main content
OpenTrials
Completed

NCT Number: NCT03185650

Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

Purpose: Characterize the depositional attributes of a specialized trans-nasal aerosol delivery device in healthy people using clinical measurements of mucociliary clearance.

Procedures (methods): 14% hypertonic saline (HS) aerosol containing the radio tracer Tc99m-sulfur colloid will be delivered via the tPAD and compared to the well characterized PARI LC Star nebulizer (7% HS) using planar gamma scintigraphy (i.e. particle clearance). The fraction of sulfur colloid particles that clear over the ensuing 24 hours with each device will indicate the fraction deposited in conducting airways.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

About this study

Purpose: This is an early device characterization study to define the fraction of delivered aerosol generated by a novel nebulizer (tPAD) that deposits in conducting airways.

Design: Open label, cross-over design, using a standard oral nebulizer (PARI LC Star) as a comparator. The order of visits will be randomized.

Methods: Gamma scintigraphy will be performed following use of each device on separate study visits.

Primary Outcome: Fraction of inhaled particles that clears over 24 hours.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 18 to 65 years (inclusive), and with a body mass index (BMI) < 30 kg/m2.
  • Non-pregnant female subjects must be either not sexually active, post-menopausal, surgically sterilized, or agree to use an appropriate "double-barrier" method (such as a diaphragm and condom); or, must currently be using a prescribed transdermal, injection, implant, or oral contraceptive during study participation.
  • Subjects who are in good health, as determined by a medical history and examination.
  • Subjects who have normal lung function with a FEV1 ≥80% predicted and a FEV1/FVC >70%.
  • Subjects who are capable of providing written informed consent in English to participate in the study.

Exclusion criteria

  • Subjects who have evidence of an upper or lower respiratory infection or clinically significant illness at entry or within 14 days of the start of dosing.
  • Subjects with lung diseases as defined by a FEV1 <80% or a FEV1/FVC <70%
  • Subjects on inhaled medications, such as short or long acting bronchodilators or inhaled corticosteroids, will be excluded.
  • Subjects with a history of allergy or intolerance to albuterol or hypertonic saline.
  • Subjects with active chronic or acute rhinosinusitis or other nasal or sinus abnormality or disease.
  • Subjects who have a present history of any clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological disorder or disease, substance abuse, or any other major disorder or disease.
  • Subjects who have had radiation exposure within the past year that would cause them to exceed Federal Regulations of 15 Rem annually by participating in this study. The study team will determine this.
  • Subjects with a history of smoking within the last 3 months.
  • Subjects with a positive pregnancy test or who are pregnant or are nursing.
  • Subjects who, in the opinion of the Principal Investigator, should not participate in the study.
  • Subjects with a BMI >30 kg/m2
  • Subjects who are taller than Height >6'2"
  • Subjects who have facial hair that they are not willing to shave

Treatment and study plan

tPAD Device

Device

A novel, transnasal aerosol generator

PARI LC Star Nebulizer

Device

Standard oral nebulizer

Primary outcomes

  1. 24-hour clearance fraction

    Time frame: 24 hours

    The percentage of initially deposited aerosol particles that clear over 24 hours will be measured with gamma scintigraphy after 24 hours

Secondary outcomes

  1. Central:Peripheral Deposition Ratio

    Time frame: 0-4 minutes after deposition

    The ratio of labelled particles initially deposited in the central and peripheral lung zones will be assessed to characterize aerosol targeting of the lung

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Parion Sciences

Registry information

Official study title

Evaluation of Regional Lung Deposition of Inhaled Saline Using the Trans-Nasal Pulmonary Aerosol Delivery Device in Healthy, Non-Smoking Adult Subjects

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 14, 2017
Registry last updated
Oct 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.